ULI1 Antibody

What is ULK1 and why is it important in research?

ULK1 (unc-51-like kinase 1) is a serine/threonine protein kinase that plays a critical role in the initiation of autophagy. It forms a stable complex with Atg13 and focal adhesion kinase (FAK) family interacting protein of 200 kDa (FIP 200), which is essential for autophagosome formation . Additionally, ULK1 phosphorylates ATG13/KIAA0652 and is involved in axon growth . The study of ULK1 is particularly important for researchers investigating autophagy mechanisms, neurodegenerative diseases, cancer, and metabolic disorders where autophagy pathways are implicated.

What applications can ULK1 antibody be used for in laboratory research?

ULK1 antibody has been validated for multiple research applications:

Note that optimal dilutions should be determined experimentally for each specific application and sample type .

How should ULK1 antibody be stored to maintain optimal reactivity?

For optimal performance of ULK1 antibody:

• Store at -20°C in the provided storage buffer (PBS with 0.02% sodium azide and 50% glycerol at pH 7.3)

• The antibody is stable for one year after shipment when properly stored

• Aliquoting is unnecessary for -20°C storage

• Smaller 20μl sizes contain 0.1% BSA for enhanced stability

• Avoid repeated freeze-thaw cycles as these can damage antibody performance and specificity

What controls should be included when designing experiments with ULK1 antibody?

When designing robust experiments with ULK1 antibody, the following controls are essential:

• Positive controls: Include samples known to express ULK1, such as HeLa cells, HepG2 cells, or skeletal muscle tissue from humans or mice

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG)

  • KD/KO validation samples (ULK1 knockdown or knockout cells, as referenced in published literature)

• Loading controls: For Western blot experiments, use housekeeping proteins (e.g., GAPDH, β-actin) to normalize protein loading

• Specificity validation: Consider using peptide competition assays to confirm the specificity of binding to the ULK1 epitope

Published literature has validated this antibody in KD/KO experimental designs, providing strong evidence for specificity .

What are the optimal antigen retrieval methods for IHC using ULK1 antibody?

For optimal antigen retrieval when performing immunohistochemistry with ULK1 antibody:

• Primary recommendation: Use TE buffer at pH 9.0 for antigen retrieval

• Alternative method: Citrate buffer at pH 6.0 may also be effective

• Time and temperature: Heat-induced epitope retrieval typically requires 15-20 minutes at 95-100°C, but exact conditions should be optimized for specific tissue types

• Tissue preparation: Formalin-fixed, paraffin-embedded tissues should be sectioned at 4-6 μm thickness for optimal results

• Background reduction: Consider including a peroxidase blocking step and appropriate protein blocking to minimize non-specific binding

The method should be optimized for each specific tissue type, fixation method, and detection system.

Why might the observed molecular weight of ULK1 differ from the calculated weight?

The calculated molecular weight of ULK1 is 113 kDa, but the observed weight in experimental conditions typically ranges from 113-140 kDa . This discrepancy may be due to:

• Post-translational modifications: ULK1 undergoes phosphorylation by multiple kinases (including AMPK and mTOR), which can add molecular weight and alter migration patterns

• Alternative splicing: Different isoforms may be expressed in different tissues

• Sample preparation conditions: Denaturing conditions, buffer composition, and reducing agents can affect protein migration

• Gel concentration and running conditions: Higher percentage gels may provide better resolution for this size range

When analyzing Western blot results, researchers should be aware of these potential variations and consider using positive controls from tissues or cell lines with confirmed ULK1 expression patterns.

How can I troubleshoot weak or absent signals when using ULK1 antibody?

If experiencing weak or absent signals with ULK1 antibody, consider the following strategies:

• Antibody concentration: Try increasing the antibody concentration (use a more concentrated dilution within the recommended range: 1:500-1:2000 for WB, 1:50-1:500 for IHC/IF)

• Antigen abundance: ULK1 expression varies by tissue and cell type; confirm expression in your sample type through literature review

• Incubation conditions:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize temperature (4°C, room temperature)

  • Use gentle agitation to improve antibody access

• Detection system sensitivity: Consider using more sensitive detection methods (e.g., enhanced chemiluminescence, tyramide signal amplification)

• Sample preparation issues:

  • Ensure proper tissue fixation and processing

  • Check protein extraction method efficiency

  • Verify protein transfer efficiency in Western blots

• Epitope masking: Post-translational modifications or protein interactions may mask the epitope; modify lysis conditions or try alternative approaches

How can ULK1 antibody be used to investigate autophagy signaling pathways?

ULK1 antibody is a powerful tool for investigating autophagy signaling pathways in various experimental contexts:

• Monitoring ULK1 activation:

  • Use phospho-specific antibodies alongside total ULK1 antibody to monitor activation states

  • Track ULK1 complex formation with its binding partners Atg13 and FIP200

• Autophagy induction studies:

  • Compare ULK1 expression and localization between basal and induced autophagy conditions

  • Use dual immunofluorescence with autophagosome markers (LC3, p62) to analyze co-localization patterns

• Upstream regulation analysis:

  • Study mTOR and AMPK regulation of ULK1 through phosphorylation state analysis

  • Investigate how nutrient deprivation affects ULK1 complex formation

• Downstream pathway investigation:

  • Track ULK1-mediated phosphorylation of substrates like ATG13

  • Analyze interaction between ULK1 and other autophagy machinery components

• Disease model applications:

  • Examine ULK1 expression/activation in cancer, neurodegenerative disease, or metabolic disorder models

  • Correlate ULK1 levels with autophagy markers in tissue samples

These approaches can be combined with genetic manipulation (siRNA, CRISPR) to establish causative relationships in autophagy signaling.

What are the considerations when using ULK1 antibody in combination with other autophagy markers?

When designing multiplex experiments with ULK1 antibody and other autophagy markers:

• Antibody compatibility:

  • Consider host species to avoid cross-reactivity in multi-labeling experiments

  • The ULK1 antibody (20986-1-AP) is rabbit-derived, so combine with mouse, rat, or goat antibodies for other markers

• Sequential detection strategy:

  • For co-localization studies, use fluorophores with minimal spectral overlap

  • Consider sequential detection protocols when using multiple rabbit antibodies

• Dynamic range alignment:

  • ULK1 may have different expression levels compared to other autophagy markers

  • Optimize dilutions of each antibody independently before combining

• Temporal considerations:

  • ULK1 acts early in the autophagy pathway, while markers like LC3-II appear later

  • Design time-course experiments to capture the complete autophagy flux

• Validation approach:

  • Use pharmacological modulators (rapamycin, bafilomycin A1) to confirm autophagy pathway engagement

  • Include appropriate positive and negative controls for each marker

These considerations ensure accurate interpretation of complex autophagy dynamics in experimental systems.

How do I interpret contradictory results between different detection methods using ULK1 antibody?

When facing contradictory results between different detection methods (e.g., Western blot showing strong expression but weak IHC signal):

• Method-specific considerations:

  • Western blot detects denatured protein, while IHC/IF detect proteins in their native conformation and cellular context

  • Epitope accessibility may differ substantially between methods

  • ULK1 antibody (20986-1-AP) has been validated for multiple methods but may perform better in certain applications

• Technical variables:

  • Antibody dilution optimization should be performed separately for each method (1:500-1:2000 for WB vs. 1:50-1:500 for IHC/IF)

  • Antigen retrieval effectiveness varies between tissue types and fixation methods

  • Signal amplification strategies differ between methods

• Biological explanations:

  • ULK1 subcellular localization may limit detection in certain methods

  • ULK1 complex formation may mask epitopes in some contexts

  • Post-translational modifications may differ between experimental conditions

• Resolution strategies:

  • Use complementary approaches to confirm results

  • Consider alternative antibodies targeting different ULK1 epitopes

  • Implement genetic validation (siRNA, CRISPR) to confirm specificity

Understanding the methodological limitations of each technique helps reconcile apparently contradictory results.

What statistical approaches are recommended for quantifying ULK1 expression or activation changes?

For robust quantification of ULK1 expression or activation:

• Western blot densitometry:

  • Normalize ULK1 signal to appropriate loading controls

  • Use linear range of detection for quantification

  • Apply ANOVA with post-hoc tests for multiple group comparisons

  • Report fold-change relative to control conditions

• Immunohistochemistry quantification:

  • Use digital image analysis for objective quantification

  • Consider H-score, Allred score, or percentage positive cells

  • Account for staining intensity and distribution

  • Analyze multiple fields/samples to capture heterogeneity

• Immunofluorescence analysis:

  • Measure mean fluorescence intensity

  • Quantify co-localization with other markers using Pearson's or Mander's coefficients

  • Consider subcellular distribution patterns

• Experimental design considerations:

  • Perform power analysis to determine appropriate sample size

  • Use blinded analysis to prevent bias

  • Include biological replicates (n≥3) and technical replicates

  • Apply appropriate tests for normality before selecting parametric/non-parametric tests

• Reporting standards:

  • Clearly state normalization methods and statistical tests

  • Include p-values and confidence intervals

  • Present raw data alongside processed results when possible

These approaches ensure scientifically sound quantification and interpretation of ULK1 expression or activation data.

How can ULK1 antibody be used in combination with proximity ligation assays (PLA) to study protein interactions?

Proximity ligation assay (PLA) combined with ULK1 antibody offers powerful insights into protein-protein interactions:

• Experimental design:

  • Use ULK1 antibody (20986-1-AP) in combination with antibodies against known or suspected interaction partners (e.g., Atg13, FIP200)

  • Primary antibodies must be from different host species (ULK1 antibody is rabbit-derived, so use mouse, rat, or goat antibodies for partners)

  • Include appropriate negative controls (single primary antibody, non-interacting protein pairs)

• Optimization strategies:

  • Titrate antibody concentrations (starting with recommended IF dilutions: 1:50-1:500)

  • Optimize fixation and permeabilization conditions for your specific cell type

  • Test different PLA probe combinations and detection systems

• Applications:

  • Investigate ULK1 complex formation under different autophagy conditions

  • Examine spatial distribution of interactions within cellular compartments

  • Study how disease conditions affect ULK1 binding partner networks

  • Monitor dynamic changes in interactions following stimuli

• Quantification approach:

  • Count discrete PLA puncta per cell

  • Analyze subcellular distribution of signals

  • Compare signal intensity across experimental conditions

PLA provides spatial resolution of protein interactions that traditional co-immunoprecipitation cannot achieve, enabling more detailed understanding of ULK1 biology in intact cells.

What considerations are important when designing ULK1 phosphorylation state studies?

ULK1 phosphorylation state studies require careful experimental design:

• Key phosphorylation sites:

  • Inhibitory sites: mTOR-mediated phosphorylation (Ser757/758)

  • Activating sites: AMPK-mediated phosphorylation (Ser317, Ser555, Ser777)

  • Consider using phospho-specific antibodies alongside total ULK1 antibody (20986-1-AP)

• Sample preparation considerations:

  • Include phosphatase inhibitors in lysis buffers

  • Process samples quickly and maintain cold conditions

  • Consider specialized phospho-protein enrichment methods for low-abundance phospho-forms

• Stimulation conditions:

  • mTOR inhibition (rapamycin, Torin1) to relieve inhibitory phosphorylation

  • AMPK activation (AICAR, metformin, glucose starvation) to promote activating phosphorylation

  • Time-course design to capture dynamic phosphorylation changes

• Detection strategies:

  • Western blot with phospho-specific antibodies

  • Phos-tag gels for mobility shift analysis

  • Mass spectrometry for comprehensive phosphosite mapping

  • Immunoprecipitation with total ULK1 antibody followed by phospho-specific detection

• Validation approaches:

  • Phosphatase treatment controls

  • Mutational analysis (phospho-mimetic or phospho-deficient ULK1 constructs)

  • Kinase inhibitor studies

Comprehensive phosphorylation analysis provides crucial insights into ULK1 regulation and autophagy pathway control mechanisms.

How can ULK1 antibody be utilized in human disease tissue studies?

ULK1 antibody applications in human disease tissue studies offer valuable insights:

• Cancer research applications:

  • The antibody has been validated in human liver cancer tissue

  • Can be used to evaluate ULK1 expression changes in tumor vs. normal tissue

  • May correlate ULK1 levels with clinical outcomes, therapeutic response, or disease progression

  • Consider using tissue microarrays for higher throughput analysis

• Neurodegenerative disease research:

  • Study ULK1 expression in autophagy-related neurodegenerative conditions

  • Compare ULK1 levels and localization in affected vs. non-affected brain regions

  • Investigate co-localization with disease-specific protein aggregates

• Metabolic disorder investigations:

  • Examine ULK1 expression in tissues relevant to metabolic regulation (liver, skeletal muscle)

  • Compare expression and activation patterns in healthy vs. disease states

  • Correlate with metabolic parameters and autophagy markers

• Technical considerations for human samples:

  • Optimize antigen retrieval protocols specifically for human tissue preservation methods

  • Consider tissue age and fixation quality

  • Use the recommended antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Include appropriate positive and negative control tissues

• Ethical and regulatory considerations:

  • Ensure proper IRB approval and informed consent

  • Consider patient privacy in data reporting

  • Follow institutional guidelines for human tissue handling

These approaches contribute to translational understanding of ULK1's role in human disease pathogenesis.

What are the methodological considerations when using ULK1 antibody with super-resolution microscopy techniques?

When combining ULK1 antibody with super-resolution microscopy:

• Sample preparation optimization:

  • Use thinner tissue sections (≤4μm) or optimally adherent cell cultures

  • Consider specialized fixation protocols (e.g., glyoxal instead of formaldehyde)

  • Optimize permeabilization to maintain structural integrity while allowing antibody access

  • Use the recommended IF dilution range as a starting point (1:50-1:500)

• Fluorophore selection:

  • Choose bright, photostable fluorophores compatible with your super-resolution method

  • Consider direct conjugation to minimize distance between epitope and fluorophore

  • For multicolor imaging, select fluorophores with appropriate spectral separation

• Controls and validation:

  • Include samples with known ULK1 expression patterns (e.g., HeLa cells)

  • Perform parallel conventional microscopy to confirm staining patterns

  • Include antibody specificity controls (peptide competition, KD/KO samples)

• Application-specific considerations:

  • STED: Use fluorophores with appropriate depletion properties

  • STORM/PALM: Consider photoswitchable fluorophores and buffer optimization

  • SIM: Ensure high signal-to-noise ratio and minimize out-of-focus light

• Analysis approaches:

  • Quantify ULK1 nanoscale clustering patterns

  • Measure precise co-localization with autophagy machinery components

  • Analyze dynamics of ULK1-positive structures during autophagy progression

Super-resolution techniques can reveal ULK1 distribution and interactions at a previously unattainable level of detail, advancing understanding of autophagy mechanisms.

How can ULK1 antibody validation be integrated with CRISPR-Cas9 gene editing approaches?

CRISPR-Cas9 gene editing provides powerful validation and research tools for ULK1 antibody applications:

• Antibody validation strategies:

  • Generate ULK1 knockout cell lines using CRISPR-Cas9

  • Create epitope-tagged ULK1 knock-in lines for correlation studies

  • Develop domain-specific deletions to map the antibody's precise epitope

  • Published research has already utilized ULK1 knockout validation approaches

• Experimental applications:

  • Compare antibody signal in wild-type vs. knockout cells across all applications (WB, IHC, IF)

  • Use truncation mutants to determine minimal epitope requirements

  • Generate phospho-mutant knock-in lines to study specific phosphorylation events

• Advanced study designs:

  • Create CRISPR activation (CRISPRa) lines to study ULK1 overexpression phenotypes

  • Develop CRISPR interference (CRISPRi) models for partial ULK1 suppression

  • Generate fluorescent protein fusions for live-cell imaging correlation

• Technical considerations:

  • Design guide RNAs targeting early exons or critical functional domains

  • Screen multiple CRISPR clones to confirm complete protein loss

  • Verify genomic editing by sequencing and protein loss by Western blot

• Controls and validation:

  • Include parental cell line controls in all experiments

  • Consider potential compensatory upregulation of related proteins (ULK2)

  • Test for off-target effects using rescue experiments

CRISPR-based approaches provide definitive validation of antibody specificity while enabling sophisticated functional studies of ULK1 biology.

What approaches can integrate ULK1 antibody staining with spatial transcriptomics?

Combining ULK1 antibody staining with spatial transcriptomics offers new insights into autophagy regulation:

• Compatible methodologies:

  • Sequential immunofluorescence and in situ hybridization

  • Multiplexed antibody staining with spatial RNA sequencing

  • Digital spatial profiling with protein and RNA detection

  • Antibody-guided spatial transcriptomics

• Sample preparation considerations:

  • Optimize fixation to preserve both protein epitopes and RNA integrity

  • Test whether recommended IHC conditions (TE buffer pH 9.0 or citrate buffer pH 6.0) maintain RNA quality

  • Consider specialized dual-preservation fixatives

  • Use RNase-free reagents throughout the protocol

• Analytical approaches:

  • Correlate ULK1 protein levels with ULK1 mRNA expression

  • Identify spatial domains with coordinated autophagy gene expression

  • Study relationship between ULK1 protein and expression of autophagy regulators

  • Analyze cell-type specific ULK1 expression patterns

• Technical validation:

  • Confirm antibody performance in the modified protocol

  • Verify RNA quality with control probes

  • Include samples with known ULK1 expression patterns (e.g., skeletal muscle)

• Applications:

  • Map autophagy regulation across tissue microenvironments

  • Study ULK1 expression in the context of cellular neighborhoods

  • Investigate post-transcriptional regulation by comparing protein and mRNA patterns